Healthcare Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
Opportunity in the Indian Life Science Industry - 2013

Opportunity in the Indian Life Science Industry - 2014

Date Published: Jan 17 2014

This report provides an insight into the Opportunity in the Indian Life Science Industry current scenario, structure and practices.

In depth Healthcare market scenario includes;
a. Healthcare Market - 2011 to 2018
b. Trends in disease burden - 1990, 2008 and 2013
c. Treatment of lifestyle diseases is expensive - Maternity, Injuries, Lifestyle Dieseases
d. India Infra vs. Global - Beds, Nurses, Physicians
e. Bed Density - 2001, 2007, 2010, 2012, 2022

$12,000.00
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

Date Published: Nov 30 2013

PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

Summary

$10,995.00
PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022

Date Published: Dec 31 2013
PharmaPoint: Microvascular Complications of Diabetes Global Drug Forecast and Market Analysis to 2022
 
$10,995.00
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

Date Published: May 31 2013

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

Summary

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis.

Highlights

Key Questions Answered

$10,995.00
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

Date Published: May 31 2013

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

Summary

$10,995.00
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

Date Published: May 31 2013

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

Summary

There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

Highlights

Key Questions Answered

$10,995.00
PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Date Published: Apr 30 2014

PharmaPoint: Non-Small Cell Lung Cancer Global Drug Forecast and Market Analysis to 2022 Event-Driven Update

 

Summary

$10,995.00
PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

Date Published: Mar 31 2014
$10,995.00
PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

Date Published: Jun 30 2013

PharmaPoint: Chronic Heart Failure - Global Drug Forecast and Market Analysis to 2022

Summary

$10,995.00
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022

Date Published: Feb 28 2014

PharmaPoint: Schizophrenia Global Drug Forecast and Market Analysis to 2022

 

Summary

$10,995.00
PharmaPoint: Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2022

Date Published: Mar 31 2014
$10,995.00
PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis

Date Published: Jan 31 2013

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis

Summary

$10,995.00
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

Date Published: Jan 31 2014
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines Global Drug Forecast and Market Analysis to 2022
Prophylactic Hepatitis B Virus Vaccines Global sales to reach over $1.1 billion by 2022.
$10,995.00
PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

Date Published: Jun 30 2013

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

Summary

$10,995.00
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

Date Published: Mar 31 2014
$10,995.00
PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022

Date Published: Jan 31 2013

PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022

Summary

$10,995.00
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Date Published: Jan 31 2014
$10,995.00
PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2022

Date Published: Jul 31 2013

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2022

Summary

There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Highlights

Key Questions Answered

$10,995.00
PharmaPoint: Crohn’s Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - Global Drug Forecast and Market Analysis to 2022

Date Published: Jan 31 2014
The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such as - 
  • Takeda’s alpha4beta7 inhibitor, Entyvio (vedolizumab)
  • Johnson & Johnson’s (J&J’s) interleukin (IL)-12/23 inhibitor, Stelara (ustekinumab)
 
$10,995.00
PharmaPoint: Postmenopausal Vaginal Atrophy - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Global Drug Forecast and Market Analysis to 2022

Date Published: Jul 31 2013

PharmaPoint: Postmenopausal Vaginal Atrophy - Global Drug Forecast and Market Analysis to 2022

Summary

$10,995.00

Pages

Shopping cart

0 Items $0.00
Market Research Special Offers
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data